Unmet Needs and Future Perspectives on the Treatment of EGFR-Mutated NSCLC
The expert panel concludes with thoughts on unmet needs and future perspectives on the treatment of patients with EGFR-mutated non–small cell lung cancer.
NSCLC with EGFR Exon 20 Insertions: Updated Data from PAPILLON
Medical oncologists review updated data from the PAPILLON trial on amivantamab plus chemotherapy and discuss the treatment of patients with NSCLC with EGFR exon 20 insertions.
MARIPOSA: First-Line Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC
Focusing on the MARIPOSA trial, the panel provides thoughts the potential role of amivantamab and lazertinib, and discusses treatment decisions upon progression.
FLAURA2: Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
Medical oncologists review the FLAURA2 study looking at osimertinib with or without chemotherapy in EGFR-mutated NSCLC and discuss patients for whom they would consider the therapy.
NSCLC: Molecular Testing in the Metastatic Setting
The discussion on biomarker testing practices for patients with non–small cell lung cancer turns its focus to the metastatic setting.
Biomarker Testing in Non–Small Cell Lung Cancer
A panel of medical oncologists introduce themselves and provide clinical insights on biomarker testing practices for patients with non–small cell lung cancer.
